期刊文献+

BP180NC16A-IgG1Fc融合蛋白真核表达体系构建 被引量:3

Eukaryotic Expression of BP180NC16A-IgG1Fc Fusion Protein
原文传递
导出
摘要 目的构建BP180NC16A-IgG1Fc融合蛋白的真核表达体系。方法①以逆转录PCR(reverse transcrip-tion-polymerase chain reaction,RT-PCR)方法从表皮组织提取总RNA中扩增编码人BP180NC16A的cDNA,与包含编码人免疫球蛋白IgG1Fc段恒定区基因的质粒pFUSE-hIgG1e4-Fc2融合,形成重组pFUSE-hIgG1e4-Fc2-BP180NC16A质粒。②重组质粒转染真核HEK293T细胞,48h后收集细胞培养上清。③通过免疫印迹的方法鉴定转染细胞上清中分泌的BP180NC16A-IgG1Fc融合蛋白。结果构建了pFUSE-hIgG1e4-Fc2-BP180NC16A真核表达质粒并在HEK293T细胞成功表达BP180NC16A-IgG1Fc融合蛋白。结论 BP180NC16A-IgG1Fc融合蛋白能够成功真核表达。 Objective To construct eukaryotic expression system of BP180NC16A-IgG1Fc fusion protein. Methods We cloned BP180NCI6A cDNA from total RNA extracted from the human epidelxnis by RT-PCR, then linked BPlg0NC16A cDNA with plasmid pFUSE-hIgGle4-Fc2 which encodes human IgG1Fc constant region, to construct recombinant plasmid pFUSE-hlgGle4-Fc2-BP180NC16A. Recombinant plasmids were then transfected in HEK 293T cells. Finally, we detected the BP180NC16A-IgG1Fc fusion protein in the supernatant by western blotting. Results HEK293T cells successfully expressed BP180NC16A-IgG1Fc fusion protein. Conclusion BP180NC16A-IgG1Fc fusion protein can be eukaryotically expressed.
出处 《中国皮肤性病学杂志》 CAS 北大核心 2012年第9期797-800,共4页 The Chinese Journal of Dermatovenereology
基金 高等学校博士学科点专项科研基金新教师基金课题(20090001120070) 国家自然科学基金青年科学基金项目(81000694)
关键词 BP180NC16A IgG1Fc 融合蛋白 真核表达 BP180NC16A IgG1Fc Fusion protein Eukaryotic expression
  • 相关文献

参考文献13

  • 1王娣,陈喜雪,朱学骏.124例大疱性类天疱疮治疗回顾[J].中华皮肤科杂志,2007,40(1):7-9. 被引量:31
  • 2Thoma-Uszynski S, Uter W, Schwietzke S, et al. BP230- and BP180- specific auto-antibodies in bullous pemphigoid [ J ]. The Journal of in- vestigative dermatology, 2004, 122 ( 6 ) : 1413 - 1422.
  • 3Giudice GJ, Emery DJ, Diaz LA. Cloning and primary, structural analy- sis of the bullous pemphigoid autoantigen BP180[J]. The Journal of in- vestigative dermatology, 1992, 99 ( 3 ) :243 - 250.
  • 4Hopkinson SB, Riddelle KS, Jones JC. Cytoplasmic donmin of the 180- kD bullous pemphigoid antigen, a hemidesmosomal component: molec- ular and cell biologic characterization [ J ]. The Journal of investigative dermatology, 1992, 99 (3) :264 - 270.
  • 5lshiko A, Shimizu H, Kikuchi A, et al. Human autoautibodies against the 230-kD bullous pemphigoid antigen ( BPAG1 ) bind only to the in- tracellular domain of the hemidesmosome, whereas those against the 180-kD bullous pemphigoid antigen (BPAG2) bind along the plasma membrane of the hemidesmosome in normal human and swine skin[ J ]. The Journal of clinical investigation, 1993, 91 (4) : 1608 - 1615.
  • 6Chen R, Ning G, Zhao ML, et al. Mast cells play a key role in neutro- phil recruitment in experimental bullous pemphigoid[ J ]. J Clin Invest,2001, 108(8): 1151 -1158.
  • 7Liu Z, Shapiro SD, Zhou X, et al. A critical role for neutrophil elastase in experimental bullous pemphigoid [ J ]. J Clin Invest, 2000, 105 ( 1 ) : 113 - 123.
  • 8Thoma-Uszynskl S, Uter W, Schwiclzke S, et al. Auloreactive T and B cells from bullous pemphigoid (BP) patients recognize epitopes clus- tered in distinct rcgioas of BPI80 and BP230[ J]. J Immunol, 2006, 176(3) :2015 -2023.
  • 9Zilhkens D, Masearo JM, Hose PA. et al. A highly sensitive enzyme- linked immunosorbent assay for the detection of circulating anti-BP180 autoantibodies in patienls with bullous pemphigoid [ J ]. J Invest Der- matol, 1997, 109 ( 5 ) :679 - 683.
  • 10Haase C, Budinger L, Borradori L, et al. Detection of lgG autoanti- bodies in the sera of patients with huiious and gestational pemphigoid: ELISA studies utilizing a baeulovirus-eneoded form of bullous pemphi- goid antigen 2 [J]. The Journal of investigative dermatology, 1998, 110(3) :282 -286.

二级参考文献6

  • 1Wojnarowska F,Kirtschig G,Highet AS,et al.Guidelines for the management of bullous pemphigoid.Br J Dermatol,2002,147 (2):214-221.
  • 2Guillaume JC,Vaillant L,Bernard P,et al.Controlled trial of azathioprine and plasma exchange in addition to prednisolone in the treatment of bullous pemphigoid.Arch Dermatol,1993,129 (1):49-53.
  • 3Chosidow O,Saada V,Diquet B,et al.Correlation between the pretreatment number of blisters and the time to control bullous pemphigoid with prednisone 1 mg/kg/day.Br J Dermatol,1992,127(2):185-186.
  • 4Bara C,Maillard H,Briand N,et al.Methotrexate for bullous pemphigoid:preliminary study.Arch Dermatol,2003,139 (11):1506-1507.
  • 5Ratnam KV.Adjuvant therapy of bullous pemphigoid with mycophenolate mofetil:old drug,new use.Singapore Med J,2001,42(10):482-484.
  • 6周小勇,李慧珠.大疱性类天疱疮89例临床分析[J].中华皮肤科杂志,2001,34(6):425-427. 被引量:17

共引文献30

同被引文献41

  • 1徐文.大疱性类天疱疮患者治疗前后血清抗BP180自身抗体检测[J].中国麻风皮肤病杂志,2007,23(4):317-318. 被引量:4
  • 2Sakuma Oyama Y, Powell A M, Oyama N, et al. Evaluation of a BP180 NC16a enzyme linked immunosorbent assay in the initial diagnosis of bullous pemphigoid[J]. Br J Dermatol,2004, 151(1) :126-131.
  • 3Kobayashi M, Amagai M,Kuroda - Kinoshita K, et al. BP180ELISA using bacterial reconbinant NC 16a protein as a diagnosticand monitoring tool for bullous pemphigoid. J Dematol Sci, 2002 ,30(3) :224-232.
  • 4Nishie W, Sawamura D, Goto M, et al. Humanization of autoanti-gen. Nat Med,2007,13(3) :378-383.
  • 5Feng S, Wu Q, Jin P, et al. Serum levels of autoantibodies toBP180 correlate with disease activity in patients with bullous pem-phigoid. Int J Dermatol, 2008,47(3) :225-228.
  • 6Ujiie H, Nishie W, Shimizu H. Pathogenesis of bullous pemphig-oid .Dermatol Clin,2011,29(3) :439-446.
  • 7Bolognia JL, Jorizzo JL, Schaffer JV. Dermatology[M]. 3rd Ed. USA: Elsevier, 2012: Chapter 28.
  • 8Van den Bergh F, Giudiee GJ. BP180 (type XVII collagen) and its role in cutaneous biology and disease[J]. Adv Dermatol, 2003, 19: 37-71.
  • 9Seppanen A, Suuronen T, Hofmann SC, et al. Distribution of collagen XVII in the human brain[J]. Brain Res, 2007, 1158: 50-56.
  • 10Van den Bergh F, Fu CL, Olague Marchan M, et al. The NC16A domain of collagen XVII plays a role in triple helix assembly and stability[J]. Biochem Biophys Res Commun, 2006, 350(4): 1032-1037.

引证文献3

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部